blood

Lowering of blood pressure achieved through use of hashish-like drug (press release)

Wednesday, August 23, 2006 by: NaturalNews
Tags: health news, Natural News, nutrition

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
Malaysia Airlines Flight 370 now clearly a government cover-up: All evidence contradicts official story
White House admits staging fake vaccination operation to gather DNA from the public
10 other companies that use the same Subway yoga mat chemical in their buns
High-dose vitamin C injections shown to annihilate cancer
Irrefutable proof we are all being sprayed with poison: 571 tons of toxic lead 'chemtrailed' into America's skies every year
EXCLUSIVE: Natural News tests flu vaccine for heavy metals, finds 25,000 times higher mercury level than EPA limit for water
Truvia sweetener a powerful pesticide; scientists shocked as fruit flies die in less than a week from eating GMO-derived erythritol
Senator who attacked Doctor Oz over dietary supplements received over $146,000 in campaign contributions from Big Pharma mega-retailer and Monsanto
Global warming data FAKED by government to fit climate change fictions
HOAX confirmed: Michelle Obama 'GMOs for children' campaign a parody of modern agricultural politics
U.S. treating meat with ammonia, bleach and antibiotics to kill the '24-hour sickness'
Ben and Jerry's switches to non-GMO, Fair Trade ice cream ingredients
Battle for humanity nearly lost: global food supply deliberately engineered to end life, not nourish it
Russia taking McDonald's to court, threatens countrywide shutdown
Diet soda, aspartame linked to premature deaths in women
Cannabis kicks Lyme disease to the curb
Elliot Rodger, like nearly all young killers, was taking psychiatric drugs (Xanax)
Harvard research links fluoridated water to ADHD, mental disorders
Delicious
A new method for lowering blood pressure (hypertension) through use of a compound that synthesizes a cannabis (hashish) plant component has been developed by a pharmacology Ph.D. student at the Hebrew University of Jerusalem School of Pharmacy.

For his work on the cardiovascular activity of cannabinoids (chemical compounds derived from cannabis), Yehoshua Maor was one of the winners of this year's Kaye Innovation Awards, presented on June 13 during the Hebrew University of Jerusalem's 69th meeting of the Board of Governors.

Cardiovascular disease (CVD) accounts for about one-third of all deaths in industrialized countries, and is the leading reason for visits there to physicians as well as for drug prescriptions. However, not all patients respond well to the drugs available. There is no "ideal' hypotensive (blood pressure lowering) drug.

The cannabis plant also known as hashish or marijuana through its chemical compounds -- cannabinoids -- has been shown to have a beneficial, hypotensive effect. However, a drawback in the therapeutic use of cannabinoids has been its undesirable psychotropic properties production of hallucinatory effects. Attempts to separate the hypotensive action from the psychotropic properties of cannabinoids have achieved only partial success until now.

Working under the supervision of Prof. Raphael Mechoulam at the Hebrew University School of Pharmacy, Maor, who was born in Brazil and immigrated to Israel in 1998, has created a synthetic version of a minor cannabis constituent named cannabigerol, which is devoid of psychotropic activity.

In laboratory experiments with rats in collaboration with Prof. Michal Horowitz of the Department of Environmental Physiology, it was found that this novel compound reduced blood pressure when administered to the rats in relatively low doses. Additional testing also showed that the compound also brought about another beneficial effect -- relaxation of the blood vessels. A further beneficial property observed in work carried out with Prof. Ruth Gallily of the Lautenberg Center for General and Tumor Immunology, was that the compounds produced an anti-inflammatory response.

Maor believes that these qualities have the potential for development of a valuable new clinical drug with a major market potential, especially for patients suffering from inflammation of the blood vessels as the result of hypertension, and others with metabolic irregularities.

Maor already has won international recognition for his work with cannabanoids, resulting from his collaborative work with Garry Milman, another Ph.D. student in the laboratory of Prof. Mechoulam, for the discovery of an endogenous compound found in the brain which causes vaso-relaxation.

Maor begin a post-doctoral fellowship in the fall at the Harvard University Medical School, where he plans to continue his research.

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.